Prognostic factors for malignant uveal melanoma. Retrospective study on 2,241 patients and recent contribution of monosomy-3 research;Facteurs pronostiques du mélanome malin de l'uvée. Étude rétrospective sur 2 241 patients et apport récent de la recherche de la monosomie 3

Journal Francais d'Ophtalmologie

Volumn 29, Issue 7, 2006, Pages 741-749

  Desjardins, L ^a   Levy Gabriel, C ^a   Lumbroso Lerouic, L ^a   Sastre, X ^a   Dendale, R ^a   Couturier, J ^a   Piperno Neumann, S ^a   Dorval, T ^a   Mariani, P ^a   Salmon, R ^a   Plancher, C ^a   Asselain, B ^a  

^a INSTITUT CURIE   (France)

Author keywords

Monosomy 3; Prognostic factors; Retinal detachment; Uveal melanoma

Indexed keywords

IODINE 125;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME 3; CLINICAL RESEARCH; CONSERVATIVE TREATMENT; CONTROLLED STUDY; ENUCLEATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOSOMY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTON THERAPY; RETINA DETACHMENT; RETROSPECTIVE STUDY; SEX DIFFERENCE; TUMOR LOCALIZATION; TUMOR VOLUME; UVEA MELANOMA;

EID: 33748894138     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-5512(06)73843-8     Document Type: Article

References (33)

1. Gambrelle J, Labialle S, Dayan G, Gayet L, Barakat S, Grange JD, Baggetto LG. Données cytogénétiques actuelles : vers la monosomie du chromosme 3 comme principal facteur pronostique du mélanome uvéal. J Fr Ophtalmol, 2004;27:1061-1067.
2. Zografos L, Perret C, Gailloud C. Conservative treatment of uveal melanoma by accelerated proton beam. In: Tumors of the eye. Proceedings of the second international symposiumon diagnosis and treatment of intraocular tumors. Geneva, Switzerland, November 23-23 1987. Edited by Bornfeld N, Gragoudas E, Höpping W, Lommatzsch P, Wessing A, Zografos L. Amsterdam/new York: Kugler publications; 1991: p. 497-506.
3. Li W, Gragoudas ES, Egan KM. Tumor basal area and metastatic death after proton beam irradiation for choroidal melanoma. Arch Ophthalmol, 2003;121:68-72.
4. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc, 1958;53:457-481.
5. Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A, 1972;35:185-207.
6. Cox D R. Regression modelsand life tables (with discussion). J R Stat SOC, 1972;B34:187-202.
7. Gragoudas ES. 1996 Jules Gonin Lecture of the Retina Research Foundation. Long-term results after proton irradiation of uveal melanomas. Graefes Arch Clin Exp Ophthalmol, 1997;235:265-267.
8. McLean IW, Keefe KS, Burnier MN. Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology, 1997;104:777-780.
9. Kroll S, Char DH, Quivey J, Castro J. A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma. Ophthalmology, 1998;105:2035-2045.
10. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res, 2001;11:255-263.
11. Isager P, Ehlers N, Overgaard J. Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas. Acta Ophthalmol Scand, 2004;82:517-525.
12. Kodjikian L, Roy P, Rouberol F, Garweg JG, Chauvel P, Manon L et al. Survival after proton-beam irradiation of uveal melanomas. Am J Ophthalmol, 2004;137:1002-1010.
13. Schmittel A, Bechrakis NE, Martus P, Mutlu D, Scheibenbogen C, Bornfeld N et al. Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma. Eur J Cancer, 2004;40:2389-2395.
14. McLean IW, Saraiva VS, Burnier MN, Jr. Pathological and prognostic features of uveal melanomas. Can J Ophthalmol, 2004;39:343-350.
15. Kivela T, Eskelin S, Makitie T, Summanen P. Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance. Invest Ophthalmol Vis Sci, 2001;42:2085-2093.
16. Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys, 2005;62:1405-1411.
17. Li W, Gragoudas ES, Egan KM. Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. Arch Ophthalmol, 2000;118:1066-1070.
18. Kodjikian L, Nguyen K, Lumbroso L, Gauthier-Villars M, Chauvel P, Plauchu H et al. Familial uveal melanoma: a report on two families and a review of the literature. Acta Ophthalrnol Scand, 2003;81:389-395.
19. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol, 2001;119:969-982.
20. Seddon JM, Gragoudas ES, Egan KM, Glynn RJ, Howard S, Fante RG et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology, 1990;97:769-777.
21. Augsburger JJ, Schneider S, Freire J, Brady LW. Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol, 1999;237:558-567.
22. Gragoudas ES, Egan KM, Seddon JM, Walsh SM, Munzenrider JE. Intraocular recurrence of uveal melanoma after proton beam irradiation. Ophthalmology, 1992;99:760-766.
23. Egger E, Zografos L, Schalenbourg A, Beati D, Bohringer T, Chamot L et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys, 2003;55:867-880.
24. Munzenrider JE, Gragoudas ES, Seddon JM, Sisterson J, McNulty P, Birnbaum S et al. Conservative treatment of uveal melanoma: probability of eye retention after proton treatment. Int J Radiat Oncol Biol Phys, 1988;15:553-558.
25. Speicher MR, Prescher G, du Manoir S, Jauch A, Horsthemke B, Bornfeld N et al. Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res, 1994;54:3817-3823.
26. Tschentscher F, Prescher G, Zeschnigk M, Horsthemke B, Lohmann DR. Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet, 2000;122:13-17.
27. Vajdic CM, Hutchins AM, Kricker A, Aitken JF, Armstrong BK, Hayward NK et al. Chromosomal gains and losses in ocular melanoma detected by comparative genomic hybridization in an Australian population-based study. Cancer Genet Cytogenet, 2003;144:12-17.
28. Sandinha MT, Farquharson MA, Roberts F. Identification of monosomy 3 in choroidal melanoma by chromosome in situ hybridisation. Br J Ophthalmol, 2004;88:1527-1532.
29. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet, 1996;347:1222-1225.
30. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer, 1997;19:22-28.
31. Patel KA, Edmondson ND, Talbot F, Parsons MA, Rennie IG, Sisley K. Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridisation. Br J Ophthalmol, 2001;81:1440-1444.
32. Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci, 2003;44:1008-1011.
33. Tschentscher F, Husing J, Holter T, Kruse E, Dresen IG, Jockel KH et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res, 2003;63:2578-2584.